Compare BBY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBY | INCY |
|---|---|---|
| Founded | 1966 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 17.0B |
| IPO Year | N/A | 1993 |
| Metric | BBY | INCY |
|---|---|---|
| Price | $72.59 | $96.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 21 |
| Target Price | $84.24 | ★ $94.94 |
| AVG Volume (30 Days) | ★ 4.0M | 2.1M |
| Earning Date | 11-25-2025 | 10-28-2025 |
| Dividend Yield | ★ 5.24% | N/A |
| EPS Growth | N/A | ★ 3878.02 |
| EPS | 3.02 | ★ 5.90 |
| Revenue | ★ $41,825,000,000.00 | $4,813,105,000.00 |
| Revenue This Year | $1.77 | $19.59 |
| Revenue Next Year | $1.32 | $10.88 |
| P/E Ratio | $24.01 | ★ $16.38 |
| Revenue Growth | N/A | ★ 18.09 |
| 52 Week Low | $54.99 | $53.56 |
| 52 Week High | $91.68 | $109.28 |
| Indicator | BBY | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 40.50 |
| Support Level | $74.24 | $100.55 |
| Resistance Level | $83.67 | $103.68 |
| Average True Range (ATR) | 2.57 | 3.22 |
| MACD | -0.41 | -1.26 |
| Stochastic Oscillator | 1.08 | 17.14 |
With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.